Azegami et al. developed a vaccine for the prevention of obesity containing ghrelin as the vaccine antigen and cyclic di-GMP as the adjuvant for intranasal administration (Table 1). The gene discussed is GHRL; the disease is obesity due to melanocortin 4 receptor deficiency.